Showing results (31-40 of 45) with videos related to

Sort By:
Pageof 5
JAMA Network Open|April 30, 2024
Intravitreal Aflibercept vs Laser Therapy for Retinopathy of Prematurity: Two-Year Efficacy and Safety Outcomes in the Nonrandomized Controlled Trial FIREFLEYE nextAndreas Stahl, Hidehiko Nakanishi, Domenico Lepore, et al.
JAMA|July 26, 2022
Effect of Intravitreal Aflibercept vs Laser Photocoagulation on Treatment Success of Retinopathy of Prematurity: The FIREFLEYE Randomized Clinical TrialAndreas Stahl, Emine A Sukgen, Wei-Chi Wu, et al.
JAMA Ophthalmology|August 3, 2023
Effect of High-Dose Intravitreal Aflibercept, 8 mg, in Patients With Neovascular Age-Related Macular Degeneration: The Phase 2 CANDELA Randomized Clinical TrialCharles C Wykoff, David M Brown, Kimberly Reed, et al.
Plant Direct|July 31, 2019
Targeted insertion of large DNA sequences by homology-directed repair or non-homologous end joining in engineered tobacco BY-2 cells using designed zinc finger nucleasesAndreas Schiermeyer, Katja Schneider, Janina Kirchhoff, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|January 9, 2016
Monotherapy Administration of Sorafenib in Patients With Non-Small Cell Lung Cancer (MISSION) Trial: A Phase III, Multicenter, Placebo-Controlled Trial of Sorafenib in Patients with Relapsed or Refractory Predominantly Nonsquamous Non-Small-Cell Lung Cancer after 2 or 3 Previous Treatment RegimensLuis Paz-Ares, Vera Hirsh, Li Zhang, et al.
Therapeutic Advances in Ophthalmology|August 21, 2025
Plain language summary of publication of the 48-week results from the PULSAR study investigating how well a new dose of aflibercept works and how safe it is for people with wet age-related macular degenerationPaolo Lanzetta, Jean-François Korobelnik, Jeffrey S Heier, et al.
Ophthalmology|September 22, 2016
Intravitreal Aflibercept for Diabetic Macular Edema: 148-Week Results from the VISTA and VIVID StudiesJeffrey S Heier, Jean-François Korobelnik, David M Brown, et al.
Therapeutic Advances in Ophthalmology|July 14, 2025
Plain language summary of publication of the 48-week results from the PHOTON study: intravitreal aflibercept 8 mg for diabetic macular edemaDavid M Brown, David S Boyer, Diana V Do, et al.
Ophthalmology|August 28, 2025
Intravitreal Aflibercept 8 mg in Neovascular Age-related Macular Degeneration: 96-Week Results from the Randomized Phase 3 PULSAR TrialJean-François Korobelnik, Paolo Lanzetta, Sergio Leal, et al.
Lancet (London, England)|March 10, 2024
Intravitreal aflibercept 8 mg in neovascular age-related macular degeneration (PULSAR): 48-week results from a randomised, double-masked, non-inferiority, phase 3 trialPaolo Lanzetta, Jean-François Korobelnik, Jeffrey S Heier, et al.
Pageof 5